HALO Stock UPDATES Halozyme Therapeutics (HALO) 9.12 10/21/2014
Post# of 273220
NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 96.97 (+1.99), HALO: 9.12 (-0.03), NLNK: 34.50 (+3.06)
Illumina (ILMN) Tops Q3 Earnings, Revenues; Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:40AM CDT
Illumina Inc.(ILMN) reported adjusted earnings of 77 cents per share in the third quarter of 2014, beating the Zacks Consensus Estimate by 37.5%.
MACK: 8.68 (unch), MDVN: 96.97 (+1.99), HALO: 9.12 (-0.03), ILMN: 179.55 (+15.08)
Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:39AM CDT
Vital Therapies, Inc. (VTL) was a big mover last session, as its shares rose almost 8% on the day.
MACK: 8.68 (unch), HALO: 9.12 (-0.03), VTL: 16.85 (+0.61), ILMN: 179.55 (+15.08)
NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose over 7% on the day.
MACK: 8.68 (unch), HALO: 9.12 (-0.03), NLNK: 34.50 (+3.06), ILMN: 179.55 (+15.08)
Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 21.21 (-0.40), SNY: 52.15 (+0.37), FOLD: 5.82 (-0.12)
Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency
M2 - Mon Oct 20, 10:35AM CDT
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced the launch and first shipments of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI) in the United States. The treatment was approved by the U.S. Food and Drug Administration (FDA) in September of this year.
HALO: 9.12 (-0.03), BAX: 68.65 (+0.71)
Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 8:39AM CDT
Regeneron Pharmaceuticals, Inc. (REGN) was a big mover last session, as its shares rose nearly 9% on the day.
MACK: 8.68 (unch), HALO: 9.12 (-0.03), EXAS: 24.22 (+0.36), REGN: 381.01 (+14.88)
Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 8.68 (unch), HALO: 9.12 (-0.03), EBS: 21.21 (-0.40), EXAS: 24.22 (+0.36)
Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant
PR Newswire - Mon Oct 20, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex® recombinant (hyaluronidase human injection). The FDA approved the use of the Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, the active ingredient used in Hylenex, and the Patheon® facility in Greenville, North Carolina, for production of finished Hylenex product.
HALO: 9.12 (-0.03)
Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.12 (-0.03), EBS: 21.21 (-0.40), RARE: 47.20 (+1.28), LGND: 50.65 (+0.41)
Novavax (NVAX) Moves Up: Stock Adds 10.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:39AM CDT
Novavax, Inc. (NVAX) was a big mover last session, as its shares rose a little over 10% on the day.
MACK: 8.68 (unch), MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), NVAX: 4.99 (-0.02)
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 9.12 (-0.03), EBS: 21.21 (-0.40), ENZ: 4.89 (+0.01), EPZM: 27.62 (+0.03)
Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:51AM CDT
Lexicon Pharmaceuticals, Inc. (LXRX) was a big mover last session, as its shares rose over 16% on the day.
MACK: 8.68 (unch), MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), LXRX: 1.35 (+0.03)
MannKind (MNKD) Worth Watching: Stock Gains 12.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:46AM CDT
MannKind (MNKD) was a big mover last session, with shares rising nearly 13% on the day.
MDVN: 96.97 (+1.99), HALO: 9.12 (-0.03), LGND: 50.65 (+0.41), MNKD: 5.53 (+0.17)
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:39AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) was a big mover last session, as its shares rose nearly 11% on the day.
MACK: 8.68 (unch), MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), PPHM: 1.48 (-0.02)
Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 7:51AM CDT
Synageva BioPharma Corp. (GEVA) was a big mover last session, as its shares rose over 7% on the day.
MACK: 8.68 (unch), MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), GEVA: 73.14 (-0.96)
Should Genomic Health (GHDX) Be in Your Portfolio Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:52PM CDT
On Oct 15, 2014, Zacks Investment Research upgraded Genomic Health Inc. (GHDX) to a Zacks Rank #1 (Strong Buy).
MDVN: 96.97 (+1.99), MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), GHDX: 33.76 (+1.00)
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:46AM CDT
Sunesis Pharmaceuticals (SNSS) was a big mover last session, with shares rising over 8% on the day.
MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), LGND: 50.65 (+0.41), SNSS: 1.47 (-0.03)
MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:39AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as its shares rose nearly 10% on the day.
MACK: 8.68 (unch), MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), MDXG: 8.65 (+0.26)